Medtronic PLC said its TYRX absorbable antibacterial envelope cut the risk of infections in patients with electronic heart implants in a trial.
Under the Wrap-It trial, the TYRX envelope reduced the risk of major infection by 40% in patients with cardiac implantable electronic devices, or CIEDs, compared to those treated with standard-of-care antibiotics given before surgery — the trial's main goal. The envelope also reduced risk of pocket infection by 61% compared to pre-operative antibiotics.
The 6,983-patient study's results were presented March 17 in the American College of Cardiology's 68th Annual Scientific Sessions.
CIEDs, such as cardiac pacemakers and implantable cardioverter defibrillators, are used to correct abnormal heart rhythms. The devices are linked to a rising rate of infections, the treatment of which can be expensive for patients.
The Dublin-based company's TYRX envelope works by encasing and stabilizing the CIEDs in a mesh that contains antibiotics minocycline and rifampin. The envelope is absorbed by the patient's body about nine weeks after it is implanted.
The TYRX envelope was approved in the U.S. and EU in 2013 and 2014, respectively.